Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts.

By Paul J Thornalley. Archives of Biochemistry and Biophysics, 2003

663 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Diabetic neuropathy: mechanisms to management. (2008, background): “P A A uthor M anuscript Aminoguanidine: Aminoguanidine (also called pimagedine) is a nucleophilic hydrazine compound and has received the most attention as a potential anti-glycation drug (Thornalley, 2003).”
Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors (2008, background): “Aminoguanidine reacts in vitro and in vivo with the a-oxoaldehydes methylglyoxal and glyoxal and ALE precursors (MDA) to form 3-amino-1,2,4-triazine derivatives (Thornalley et al., 2000; Thornalley, 2003).”
Aldehyde Sources, Metabolism, Molecular Toxicity Mechanisms, and Possible Effects on Human Health (2005, background): “Evidence for the hypothesis that α-oxoaldehydes were cytotoxic was the protection by α-oxoaldehyde reactive agents D-penicillamine, aminoguanidine, and semicarbazide against αoxoaldehyde cytotoxicity (Thornalley, 2003; Wondrak et al., 2002).”